233 related articles for article (PubMed ID: 19324273)
1. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.
Wei L; Ye Y; Wadas TJ; Lewis JS; Welch MJ; Achilefu S; Anderson CJ
Nucl Med Biol; 2009 Apr; 36(3):277-85. PubMed ID: 19324273
[TBL] [Abstract][Full Text] [Related]
2. Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide.
Huang CW; Li Z; Cai H; Shahinian T; Conti PS
Bioconjug Chem; 2011 Feb; 22(2):256-63. PubMed ID: 21244039
[TBL] [Abstract][Full Text] [Related]
3. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
4. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
[TBL] [Abstract][Full Text] [Related]
5. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.
Sprague JE; Kitaura H; Zou W; Ye Y; Achilefu S; Weilbaecher KN; Teitelbaum SL; Anderson CJ
J Nucl Med; 2007 Feb; 48(2):311-8. PubMed ID: 17268030
[TBL] [Abstract][Full Text] [Related]
7. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
8.
Ocak M; Beaino W; White A; Zeng D; Cai Z; Anderson CJ
Cancer Biother Radiopharm; 2018 Mar; 33(2):74-83. PubMed ID: 29634417
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.
Yang J; Guo H; Miao Y
Nucl Med Biol; 2010 Nov; 37(8):873-83. PubMed ID: 21055617
[TBL] [Abstract][Full Text] [Related]
10. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
11. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
12. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ
Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
14. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
15. [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.
Knetsch PA; Petrik M; Rangger C; Seidel G; Pietzsch HJ; Virgolini I; Decristoforo C; Haubner R
Nucl Med Biol; 2013 Jan; 40(1):65-72. PubMed ID: 23102540
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
17. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
Li ZB; Chen K; Chen X
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
Hernandez R; Czerwinski A; Chakravarty R; Graves SA; Yang Y; England CG; Nickles RJ; Valenzuela F; Cai W
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
